How can genomics inform the public health response to the threat of meningococcal disease?

National attention has been gripped by the recent meningitis outbreak which has claimed two lives in Kent this March. This acute disease, although thankfully rare, has a rapid onset and can result in hospitalisation and death. In this post, we unpack the role that genomics has played in enabling a rapid public health response and put this in the context of wider changes in the UK public health response infrastructure.

First, a little background on meningococcus

Meningitis, the inflammation of the protective membranes that surround the brain and spinal cord (the meninges), is a devastating disease caused by a huge array of pathogens and other non-transmissible causes. Neisseria meningitidis (Nm) is a common bacterium that lives asymptomatically in the nose and throat in around 10% of the general population and is a leading cause of meningitis.

Rarely, Nm breaches the mucosal barrier, entering the blood stream, and can progress to life threatening disease. This predominantly affects children and young adults, whose carriage rate is generally higher at 20-35%, peaking at age 19 and attributed to differences in contact patterns and social behaviour. This is known as invasive meningococcal disease (IMD), leading to acute systemic infection – namely sepsis or meningitis. IMD is so dangerous, as has been widely reported in the media, because symptoms progress to acute disease quickly and, if not recognised, can result in high morbidity and mortality.

There are at least 25 different species of Nm, not all of which are disease causing. The genome of Nm shows a pronounced ability to rearrange, gain or lose genetic material, known as ‘genome plasticity’. The high level of plasticity of Nm is mostly as a result of high rates of genetic recombination and alteration of protein expression in response to host and environmental factors. This ability to adapt rapidly to environmental changes alters the way that the immune system responds to infection, driving invasive infection. Significant efforts have been devoted by the scientific community to understand the Nm bacterium and thus to contribute to understanding IMD and the public health impact of the disease. The use, and sharing, of whole genome sequencing data from Nm isolates has expanded our understanding of the diversity of this species, its evolution and how more virulent (disease-causing) strains emerge.

Meningitis in the UK

The outbreak of meningitis in Kent, UK in March 2026 has made for worrying front page headlines. An intensive public health campaign, led by UKHSA, has been launched to respond to ongoing cases and prevent further transmission. This includes contact tracing (which identified a local nightclub, Club Chemistry, in Canterbury as the site of the primary transmission event between 5 and 7 March), the prescription of more than 10,000 preventative antibiotics and vaccination of pre-teens and teenagers.

While this appears to have been an effective response, with no new cases being identified in recent days, this incident has raised many questions. UKHSA have commented that this outbreak was unusual in size and pace compared to past outbreaks. In parallel to the public health response, an active scientific epidemiological investigation is unfolding as we seek to try to understand why this outbreak became so devastating.

What do we know so far?

This outbreak of invasive meningococcal disease (IMD) was caused by serogroup B meningococcus, which is the most common type of Nm in the UK. The outbreak has been traced specifically to a subtype of the predominant UK strain, that has been circulating in the UK for approximately 5 years. Potential drivers of this outbreak include:

1. Biological properties of the circulating bacterial strain
2. Immunity in the affected population
3. Social and environmental factors

A change in any of these drivers can facilitate an immune system breach, which can then result in IMD. What this means in practice is that:

• The phenotype – the biological properties displayed outwardly by the organism – play a large role in the development of disease. Wide phenotypic variation of Nm, particularly in the proliferation phase, seems to tip the balance between individuals carrying the bacteria harmlessly and developing IMD. Most invasive Nm lineages are coated in a protective ‘capsule’ which allows them to breach the mucosal barrier and evade the host immune system response.
• The risk of IMD is observed to be higher after the introduction of a new strain, with immunity increasing as time passes. The current UK outbreak strain was first identified in 2020, which is regarded as a recent emergence. This suggests that pre-existing immunity to this strain may have been low, leaving people at increased risk of infection.
• The risk of exposure is higher in young adults with histories of recent entry into shared accommodation (for example university residences), intense social mixing, close intimate contact and smoking behaviours. The current epidemiology of the UK outbreak places confirmed patients squarely within this higher risk group.

It is currently early days and UKHSA believe that it is unlikely that any one factor explains this outbreak, rather it is the combination of contributing factors.

How can we better understand the relationship between humans and Nm?

Understanding infectious disease must address the role of the host (human) and pathogen. Nm is a human-host restricted pathogen that, through co-evolutionary pressure and adaptation, has specialised over time. Host genomics supports a better understanding of the factors that lead to invasive disease, particularly where the majority, when infected, do not develop severe disease. The strongest evidence for host susceptibility to infection comes from study of rare monogenic disorders, providing insights into key elements of the host response and how disruption leads to IMD.

For example, loss of any number of genes involved in the complement pathway (C5, C6, C8A, C8B or C9) causes an autosomal recessive monogenic disorder leading to increased susceptibility to Nm infection. The complement pathway is responsible for the immune system finding and ‘consuming’ bacteria by phagocytosis. This is complemented by research that shows how Nm has adapted to evade recognition by complement factor H, showing that infection is the sum of the pathogen and host. Bringing together host and pathogen genomic research can more readily identify patterns and these lessons inform translational research into new treatments or vaccines.

Given the strength of evidence, unusual susceptibility may already justify using whole genome sequencing (of the patient) to identify rare genetic causes to explain severe illness and better guide care. However, rare susceptibility is unlikely to explain an outbreak of this size and it is more likely explained by environmental drivers under investigation by the UKHSA.

Genomics central to these innovations

Whole genome sequencing is increasingly central to global pathogen responses, especially in outbreak situations. It has enabled us to examine bacteria with unprecedented levels of resolution, improving our understanding of pathogens and unlocking insights in close to real-time. For meningitis, enablers include large genome projects, such as the Meningitis Research Foundation – Meningococcus Genome Library (MRF-MGL) and the MenAfriCar surveillance project, to support detection and characterisation for contact tracing, antimicrobial resistance prediction and vaccine coverage. All are critical to guiding an effective public health response.

The UKHSA is already betting on genomics, underpinned by the Pathogen Genomics Strategy launched in 2024. The MenB technical brief demonstrates that genomics is a critical tool for managing outbreaks and a large body of evidence demonstrating the benefit of using WGS in outbreaks across different pathogens has developed; yet the infrastructure, funding and capacity to enable this on a large or routine scale needs to be put in place.

The COVID-19 pandemic genomic investigations demonstrate what can be achieved when all available time, money and expertise are assigned to a common goal. However this model is unrealistic and unsustainable outside of a national emergency of that sort. An update on the UKHSA’s implementation of the five-year Pathogen Genomics Strategy would nonetheless be timely and valuable to show what steps the UKHSA has taken towards the achieving the ambitions set out and how they intend to move forward, particularly considering the focus on data sharing, stimulating innovation in pathogen genomics and driving value for money from this investment.

Take home message

• Genomics has enabled a rapid response to an outbreak of meningitis that was unusual in size and the number of patients who became severely unwell
• It will take time to understand the key drivers of this outbreak; it is likely that several factors combined to make it particularly devastating and each of these, and their interaction in this case, will need to be investigated carefully
• Looking beyond the pathogen, to consider the host, may be one gap in the public health response that has not yet been explored
• Genomics is clearly a significant pillar in the public health response, delivered by UKHSA. An update on implementation plans would provide timely insights into progress on the Pathogen Genomics Strategy.